Over the past twenty-five years, Novartis has helped to pioneer a paradigm shift in our understanding of chronic myeloid leukemia (CML), reshaping how scientists and clinicians approach this rare blood cancer and helping to turn a once-deadly disease into a manageable chronic condition for most patients.

From apprentice to team leader: Nicole Wegscheidler's career shows how curiosity, resilience and growth can unlock unexpected opportunities.

Our innovations matter only when they reach the people who need them. Yet millions live with heart disease or cancer without knowing it or have limited access to care – especially those in low-income, rural or other hard-to-reach communities.

Novartis has earned a spot among the world’s top performers, ranking #19 in TIME and Statista’s World’s Best Companies 2026 – a significant rise from #114 last year. The recognition reflects progress across three critical areas: business performance, workplace experience, and sustainability.

Novartis has reached the highest performance tier in the CCLA Corporate Mental Health Benchmark, recognizing a comprehensive approach to workplace mental health, wellbeing and employee support.

Novartis is working with community partners to bring heart disease and cancer screening, information and support closer to where people are.

Nazem Atassi, Development Unit Head for Neuroscience and Gene Therapies, Global Drug Development.

Millions of people around the world continue to face barriers to prevention, diagnosis and treatment for chronic diseases such as heart disease and cancer. To help address these gaps, Novartis is scaling its community health programs from 11 to more than 30 countries by 2030, working alongside local partners to connect more people to care.

Christian Diehl, Chief Data & Digital Officer, Novartis Biomedical Research